The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! About 1.86 million shares traded hands or 46.46% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 42.97% since March 7, 2016 and is downtrending. It has underperformed by 50.56% the S&P500.
The move comes after 7 months positive chart setup for the $2.89B company. It was reported on Oct, 10 by Barchart.com. We have $54.07 PT which if reached, will make NASDAQ:ALNY worth $1.50B more.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was upgraded by JP Morgan to “Overweight” on Friday, March 11. The firm earned “Hold” rating on Saturday, August 22 by TheStreet. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Overweight” rating by Piper Jaffray on Monday, August 31. Goldman Sachs maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Goldman Sachs has “Neutral” rating and $34 price target. The firm has “Outperform” rating by Credit Suisse given on Thursday, October 6. Jefferies maintained the shares of ALNY in a report on Thursday, October 6 with “Buy” rating. The company was initiated on Wednesday, January 20 by Credit Suisse. The firm has “Buy” rating given on Friday, October 23 by Jefferies. On Friday, August 5 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Chardan Capital Markets with “Buy” on Thursday, October 6.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in Q2 2016. Its down 0.21, from 1.48 in 2016Q1. The ratio fall, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Aureus Asset Mgmt Ltd Liability holds 2.99% or 164,161 shares in its portfolio. Renaissance Lc holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 18,673 shares. Oregon Pub Employees Retirement Fund accumulated 0% or 100 shares. Royal Bank Of Canada reported 51,314 shares or 0% of all its holdings. Blackrock Japan holds 89,754 shares or 0.02% of its portfolio. Federated Invsts Pa accumulated 0% or 10,561 shares. Dodge Cox, a California-based fund reported 2.52 million shares. Toronto Dominion Natl Bank has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blue Ridge Capital Ltd Com holds 0.95% or 1.32M shares in its portfolio. Commonwealth Equity has 5,704 shares for 0% of their US portfolio. Moreover, Alliancebernstein L P has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 50,214 shares. Evercore Wealth Limited Liability Com has 600 shares for 0% of their US portfolio. Atika Llc has invested 0.33% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Bluemountain Management Limited Company, a New York-based fund reported 9,608 shares. Blackrock Grp Limited accumulated 0.02% or 557,458 shares.
Insider Transactions: Since April 19, 2016, the stock had 0 insider purchases, and 2 insider sales for $3.98 million net activity. $1.95M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by MARAGANORE JOHN on Tuesday, July 19.
More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016, also Fool.com with their article: “What’s Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?” published on October 07, 2016, Fool.com published: “Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.” on September 24, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Marketwatch.com and their article: “Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety …” published on October 06, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: October 06, 2016.
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.